CDC backs routine use of Prevnar 13 in adults over 65

The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommended routine use of pneumococcal vaccine Prevnar/ Prevenar 13 from Pfizer Inc. (NYSE:PFE) for adults 65 years of age and older. According to the recommendation, adults over 65 who have not previously received a pneumococcal vaccine should receive Prevnar 13 followed by Pneumovax 23 pneumococcal vaccine from Merck & Co. Inc. (NYSE:MRK). Adults who have previously been vaccinated with Pneumovax 23 should receive just Prevnar 13. ACIP's recommendation now goes to the CDC and HHS directors. ...